![Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Journal for ImmunoTherapy of Cancer | Full Text Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-018-0420-0/MediaObjects/40425_2018_420_Fig4_HTML.png)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Journal for ImmunoTherapy of Cancer | Full Text
![Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-6685-y/MediaObjects/12885_2020_6685_Fig1_HTML.png)
Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text
![Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis](https://www.jcancer.org/v11/p7202/jcav11p7202g001.jpg)
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
![Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-49250-6/MediaObjects/41598_2019_49250_Fig2_HTML.png)
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
![Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram](https://www.researchgate.net/publication/263702696/figure/fig2/AS:667619061411855@1536184196912/Overall-survival-curves-for-A-all-140-patients-with-metastatic-renal-cell-carcinoma-and.png)
Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram
![JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma](https://pub.mdpi-res.com/jcm/jcm-09-01594/article_deploy/html/images/jcm-09-01594-g001.png?1590322290)
JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
![Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01694-6/MediaObjects/41591_2022_1694_Fig1_HTML.png)
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
![Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2065179678/2066267922/gr1.jpg)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology
![Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/6/3415/F2.large.jpg)
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
![Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/bf31c0cc-87e7-4ff3-a158-bd339705b425/mfig001.jpg)
Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library
![Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram](https://www.researchgate.net/publication/316168352/figure/fig3/AS:670350929039373@1536835524983/Kaplan-Meier-curve-depicting-the-overall-survival-of-359-metastatic-papillary-renal-cell.png)
Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram
![Frontiers | Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database Frontiers | Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database](https://www.frontiersin.org/files/Articles/716455/fsurg-08-716455-HTML-r1/image_m/fsurg-08-716455-g001.jpg)
Frontiers | Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database
![Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - Annals of Oncology Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/2f2bbc3b-51cb-4aeb-b415-b5b749fd16ea/gr1.jpg)
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - Annals of Oncology
![Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/473816/473816_Thumb_400.jpg)
Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma
![Personalized Management of Advanced Kidney Cancer | American Society of Clinical Oncology Educational Book Personalized Management of Advanced Kidney Cancer | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2018/edbk.2018.38/edbk_201215/20180622/images/large/edbk_201215_table1.jpeg)